These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
178 related articles for article (PubMed ID: 35106843)
1. Synthetic Antibody-Rhamnose Cluster Conjugates Show Potent Complement-Dependent Cell Killing by Recruiting Natural Antibodies. Ou C; Prabhu SK; Zhang X; Zong G; Yang Q; Wang LX Chemistry; 2022 Mar; 28(16):e202200146. PubMed ID: 35106843 [TBL] [Abstract][Full Text] [Related]
2. Chemical Synthesis of Antibody-Hapten Conjugates Capable of Recruiting the Endogenous Antibody to Magnify the Fc Effector Immunity of Antibody for Cancer Immunotherapy. Zhou K; Hong H; Lin H; Gong L; Li D; Shi J; Zhou Z; Xu F; Wu Z J Med Chem; 2022 Jan; 65(1):323-332. PubMed ID: 34962121 [TBL] [Abstract][Full Text] [Related]
3. Rhamnose modified antibodies show improved immune killing towards EGFR-positive solid tumor cells. Hong H; Zhao J; Zhou K; Li Y; Li D; Wu Z Carbohydr Res; 2024 Feb; 536():109038. PubMed ID: 38219633 [TBL] [Abstract][Full Text] [Related]
4. Synthesis and Evaluation of Three Azide-Modified Disaccharide Oxazolines as Enzyme Substrates for Single-Step Fc Glycan-Mediated Antibody-Drug Conjugation. Zhang X; Ou C; Liu H; Wang LX Bioconjug Chem; 2022 Jun; 33(6):1179-1191. PubMed ID: 35543724 [TBL] [Abstract][Full Text] [Related]
5. Crystallizable Fragment Glycoengineering for Therapeutic Antibodies Development. Li W; Zhu Z; Chen W; Feng Y; Dimitrov DS Front Immunol; 2017; 8():1554. PubMed ID: 29181010 [TBL] [Abstract][Full Text] [Related]
6. One-Pot Conversion of Free Sialoglycans to Functionalized Glycan Oxazolines and Efficient Synthesis of Homogeneous Antibody-Drug Conjugates through Site-Specific Chemoenzymatic Glycan Remodeling. Ou C; Li C; Zhang R; Yang Q; Zong G; Dai Y; Francis RL; Bournazos S; Ravetch JV; Wang LX Bioconjug Chem; 2021 Aug; 32(8):1888-1897. PubMed ID: 34351736 [TBL] [Abstract][Full Text] [Related]
7. General and Robust Chemoenzymatic Method for Glycan-Mediated Site-Specific Labeling and Conjugation of Antibodies: Facile Synthesis of Homogeneous Antibody-Drug Conjugates. Zhang X; Ou C; Liu H; Prabhu SK; Li C; Yang Q; Wang LX ACS Chem Biol; 2021 Nov; 16(11):2502-2514. PubMed ID: 34569782 [TBL] [Abstract][Full Text] [Related]
8. Chemoenzymatic Synthesis of a Rhamnose-Functionalized Bispecific Nanobody as a Bispecific Antibody Mimic for Cancer Immunotherapy. Hong H; Lin H; Li D; Gong L; Zhou K; Li Y; Yu H; Zhao K; Shi J; Zhou Z; Huang Z; Wu Z Angew Chem Int Ed Engl; 2022 Sep; 61(38):e202208773. PubMed ID: 35891606 [TBL] [Abstract][Full Text] [Related]
9. Site-Specific Chemoenzymatic Conjugation of High-Affinity M6P Glycan Ligands to Antibodies for Targeted Protein Degradation. Zhang X; Liu H; He J; Ou C; Donahue TC; Muthana MM; Su L; Wang LX ACS Chem Biol; 2022 Nov; 17(11):3013-3023. PubMed ID: 35316032 [TBL] [Abstract][Full Text] [Related]
10. An Fc engineering approach that modulates antibody-dependent cytokine release without altering cell-killing functions. Kinder M; Greenplate AR; Strohl WR; Jordan RE; Brezski RJ MAbs; 2015; 7(3):494-504. PubMed ID: 25933349 [TBL] [Abstract][Full Text] [Related]
11. Homogeneous Antibody-Drug Conjugates via Glycoengineering. Tang F; Shi W; Huang W Methods Mol Biol; 2019; 2033():221-238. PubMed ID: 31332757 [TBL] [Abstract][Full Text] [Related]
12. Effects of terminal galactose residues in mannose α1-6 arm of Fc-glycan on the effector functions of therapeutic monoclonal antibodies. Aoyama M; Hashii N; Tsukimura W; Osumi K; Harazono A; Tada M; Kiyoshi M; Matsuda A; Ishii-Watabe A MAbs; 2019 Jul; 11(5):826-836. PubMed ID: 30990348 [TBL] [Abstract][Full Text] [Related]
13. Protease-Activation of Fc-Masked Therapeutic Antibodies to Alleviate Off-Tumor Cytotoxicity. Elter A; Yanakieva D; Fiebig D; Hallstein K; Becker S; Betz U; Kolmar H Front Immunol; 2021; 12():715719. PubMed ID: 34413859 [TBL] [Abstract][Full Text] [Related]
14. Rhamnose glycoconjugates for the recruitment of endogenous anti-carbohydrate antibodies to tumor cells. Sheridan RT; Hudon J; Hank JA; Sondel PM; Kiessling LL Chembiochem; 2014 Jul; 15(10):1393-8. PubMed ID: 24909955 [TBL] [Abstract][Full Text] [Related]
16. Glycoengineered Monoclonal Antibodies with Homogeneous Glycan (M3, G0, G2, and A2) Using a Chemoenzymatic Approach Have Different Affinities for FcγRIIIa and Variable Antibody-Dependent Cellular Cytotoxicity Activities. Kurogochi M; Mori M; Osumi K; Tojino M; Sugawara S; Takashima S; Hirose Y; Tsukimura W; Mizuno M; Amano J; Matsuda A; Tomita M; Takayanagi A; Shoda S; Shirai T PLoS One; 2015; 10(7):e0132848. PubMed ID: 26200113 [TBL] [Abstract][Full Text] [Related]
17. Influence of N-glycosylation on effector functions and thermal stability of glycoengineered IgG1 monoclonal antibody with homogeneous glycoforms. Wada R; Matsui M; Kawasaki N MAbs; 2019; 11(2):350-372. PubMed ID: 30466347 [TBL] [Abstract][Full Text] [Related]
18. Repurposing the Pentameric B-Subunit of Shiga Toxin for Gb3-Targeted Immunotherapy of Colorectal Cancer by Rhamnose Conjugation. Liu Z; Li X; Lu Z; Qin X; Hong H; Zhou Z; Pieters RJ; Shi J; Wu Z J Pharm Sci; 2022 Oct; 111(10):2719-2729. PubMed ID: 35905973 [TBL] [Abstract][Full Text] [Related]
19. Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions. Moore GL; Chen H; Karki S; Lazar GA MAbs; 2010; 2(2):181-9. PubMed ID: 20150767 [TBL] [Abstract][Full Text] [Related]